Your browser is no longer supported. Please, upgrade your browser.
Settings
LPCN Lipocine Inc. daily Stock Chart
LPCN [NASD]
Lipocine Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own5.79% Shs Outstand21.34M Perf Week3.05%
Market Cap36.06M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float20.22M Perf Month6.29%
Income-0.60M PEG- EPS next Q-0.13 Inst Own12.50% Short Float1.56% Perf Quarter5.62%
Sales0.40M P/S90.16 EPS this Y62.60% Inst Trans-0.89% Short Ratio0.53 Perf Half Y17.36%
Book/sh0.55 P/B3.07 EPS next Y-17.30% ROA-52.40% Target Price7.63 Perf Year30.00%
Cash/sh0.79 P/C2.13 EPS next 5Y- ROE-89.80% 52W Range1.03 - 2.64 Perf YTD30.00%
Dividend- P/FCF- EPS past 5Y29.80% ROI- 52W High-35.98% Beta0.64
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low64.08% ATR0.12
Employees14 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)57.54 Volatility6.86% 8.16%
OptionableYes Debt/Eq0.86 EPS Q/Q48.60% Profit Margin- Rel Volume0.48 Prev Close1.63
ShortableYes LT Debt/Eq0.67 EarningsMar 11 AMC Payout- Avg Volume599.22K Price1.69
Recom- SMA203.13% SMA5012.33% SMA20019.42% Volume290,031 Change3.68%
Jan-12-18Reiterated H.C. Wainwright Buy $10 → $3
Jan-11-18Downgrade Canaccord Genuity Buy → Hold $11 → $2
Dec-08-17Resumed H.C. Wainwright Buy $10
Oct-07-16Initiated H.C. Wainwright Buy $25
Jul-22-15Initiated ROTH Capital Buy $36
Jun-23-15Initiated Canaccord Genuity Buy $15
Feb-14-19 07:00AM  Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects PR Newswire
Jan-25-19 02:00PM  LPCN: Soldiering on and Winning Some Battles Zacks Small Cap Research
Jan-24-19 09:30AM  4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19) ACCESSWIRE
08:00AM  Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects PR Newswire
Jan-17-19 10:00AM  Lipocine's NASH Candidate Shows Promise In Liver Fat Study Benzinga +18.24%
09:10AM  Lipocine's stock rockets on premarket leading volume after upbeat liver fat study results MarketWatch
07:00AM  Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results PR Newswire
Jan-14-19 08:00AM  USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus PR Newswire
Dec-31-18 08:00AM  Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO PR Newswire +21.50%
Dec-21-18 08:00AM  Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference PR Newswire
Dec-20-18 08:00AM  Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD PR Newswire
Nov-26-18 10:30AM  LPCN: Tlando Readouts Coming Soon; NDA to Follow Zacks Small Cap Research
Nov-22-18 11:30AM  Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic? Simply Wall St.
Nov-19-18 08:25AM  Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 08:49AM  Lipocine: 3Q Earnings Snapshot Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018 PR Newswire
Nov-05-18 08:00AM  Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH PR Newswire
Nov-01-18 04:00PM  Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO PR Newswire
Oct-29-18 01:15PM  LPCN: Androgen Therapy in NASH: A Comprehensive Approach Zacks Small Cap Research
Oct-11-18 08:00AM  Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018 PR Newswire
Sep-25-18 08:00AM  Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Sep-19-18 08:51AM  Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)? Simply Wall St.
Aug-29-18 10:00AM  LPCN: 2Q:18 Operational and Financial Results Zacks Small Cap Research
Aug-07-18 08:32AM  Lipocine: 2Q Earnings Snapshot Associated Press
07:30AM  Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018 PR Newswire
Aug-02-18 08:00AM  Lipocine to Present at the Canaccord Genuity 38th Annual Growth Conference PR Newswire
Jun-18-18 07:05AM  Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks ACCESSWIRE
Jun-07-18 08:00AM  Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO PR Newswire
May-16-18 08:59PM  Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN) Simply Wall St.
May-14-18 10:35AM  LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response Zacks Small Cap Research +15.45%
May-11-18 07:00AM  Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks ACCESSWIRE
May-09-18 09:45AM  Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks Benzinga -35.96%
08:45AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:09AM  Lipocine shares drop 38% after FDA fails to approve testosterone replacement therapy MarketWatch
06:59AM  Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration PR Newswire
May-08-18 07:55AM  Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure Benzinga +13.37%
May-07-18 08:27AM  Lipocine: 1Q Earnings Snapshot Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018 PR Newswire
Apr-23-18 08:00AM  Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN GlobeNewswire -9.09%
Apr-20-18 07:20AM  Free Research Report as Lipocine Announced FY17 Financial Results ACCESSWIRE
Apr-02-18 10:15AM  LPCN: Coming at the FDA Like a Spider Monkey Zacks Small Cap Research
Mar-21-18 08:00AM  Lipocine to Present at the 17th Annual Needham Healthcare Conference PR Newswire
Mar-14-18 08:00AM  Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference PR Newswire
Mar-12-18 08:00AM  Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017 PR Newswire -6.33%
Mar-06-18 07:55AM  Interested In Lipocine Inc (NASDAQ:LPCN)? Heres What Its Recent Performance Looks Like Simply Wall St.
Mar-05-18 08:00AM  Lipocine to Present at the 30th Annual ROTH Conference PR Newswire
Mar-02-18 10:50PM  LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. LPCN Business Wire +8.28%
Feb-28-18 08:20AM  Todays Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals ACCESSWIRE +25.00%
Feb-27-18 11:45AM  Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating Benzinga +16.03%
Feb-16-18 10:50PM  LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN PR Newswire
08:00AM  Lipocine Announces Settlement of Securities Class Action Lawsuit PR Newswire
Feb-08-18 08:00AM  Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank PR Newswire -6.98%
Feb-07-18 04:01PM  Lipocine to Present at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Feb-02-18 10:50PM  LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. LPCN Business Wire -6.99%
Jan-29-18 05:12PM  Harwood Feffer LLP Announces Investigation of Lipocine Inc. Business Wire +7.63%
Jan-19-18 11:00AM  LPCN: AdCom Votes 6:13 Against Tlando Zacks Small Cap Research
Jan-12-18 05:06PM  LIPOCINE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine, Inc. To Contact The Firm ACCESSWIRE -8.56%
Jan-11-18 02:49PM  Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades Benzinga -45.95%
11:52AM  FDA Advisers Slam Lipocine's Testosterone Pill, Raising Doubts About 'Low T' Drugs Forbes
06:44AM  Whats Next For Lipocine After A Disappointing Panel Review? Market Exclusive
Jan-10-18 05:07PM  Lipocine Inc (LPCN) Fails to Convince FDA Advisory Committee of TLANDOs Merit; Shares Decline Over 50% SmarterAnalyst
04:40PM  Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism PR Newswire
Jan-08-18 11:46AM  The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In Benzinga +12.87%
Jan-04-18 08:00AM  Lipocine Anticipating Results from Two Near Term FDA Dates, PDUFA and BRUDAC ACCESSWIRE
Nov-22-17 01:00PM  LPCN: Third Quarter Operational and Financial Results Zacks Small Cap Research
Nov-17-17 08:00AM  U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged GlobeNewswire -5.71%
Nov-08-17 08:09AM  Lipocine reports 3Q loss Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 GlobeNewswire
Oct-18-17 08:00AM  FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 GlobeNewswire +7.55%
Sep-22-17 01:00PM  LPCN: Advisory Committee Required and USPTO Issues Motion for Tlando Zacks Small Cap Research
Sep-21-17 08:00AM  Lipocine Announces Motions Decision by USPTO in Interference Against Clarus GlobeNewswire
Sep-20-17 08:00AM  Lipocine Announces FDA Advisory Committee Meeting for TLANDO GlobeNewswire
Sep-19-17 03:02PM  Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-05-17 08:00AM  Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-14-17 10:30AM  LPCN: Second Quarter Operational and Financial Results Zacks Small Cap Research
08:00AM  Lipocine Announces FDA Acknowledgement of TLANDO (LPCN 1021) NDA Resubmission; PDUFA Goal Date, February 8, 2018 GlobeNewswire
Aug-09-17 08:00AM  Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism GlobeNewswire
Aug-07-17 11:59PM  Lipocine reports 2Q loss Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 GlobeNewswire
Aug-02-17 08:00AM  Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire -5.19%
Jun-26-17 08:00AM  Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth GlobeNewswire -6.41%
Jun-21-17 08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Lipocine and Portola Pharmaceuticals Accesswire
Jun-19-17 04:00PM  Lipocine Validates No Titration Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate GlobeNewswire
12:02PM  Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021 GlobeNewswire
Jun-02-17 08:00AM  Lipocine to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
May-16-17 04:00PM  LPCN 1021 Readout in June; 1Q:17 R&D Costs Lower Zacks Small Cap Research -8.51%
May-09-17 02:07PM  Robbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action Business Wire
May-08-17 08:12AM  Lipocine reports 1Q loss Associated Press
08:00AM  Lipocine Announces Financial and Operational Results for the First Quarter 2017 GlobeNewswire
Apr-24-17 08:00AM  Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials GlobeNewswire
Mar-28-17 08:00AM  Lipocine to Present at 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-14-17 08:00AM  Lipocine to Present at 27th Annual Oppenheimer Conference GlobeNewswire
Mar-13-17 08:02AM  LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +11.25%
07:00AM  LPCN: Conserving Cash to Fund Underway DV and DF Studies Zacks Small Cap Research
Mar-10-17 01:04PM  LIPOCINE INC. Financials
Mar-06-17 04:07PM  LIPOCINE INC. Files SEC form 8-K, Other Events
04:05PM  LIPOCINE INC. Files SEC form 10-K, Annual Report
04:00PM  Lipocine Announces Financial and Operational Results for the Full Year of 2016 GlobeNewswire
08:00AM  Lipocine to Present at 29th Annual ROTH Conference GlobeNewswire
Feb-15-17 08:42AM  LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.